Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine - PubMed (original) (raw)
. 2006 Apr 12;295(14):1668-74.
doi: 10.1001/jama.295.14.1668.
Thomas R Talbot, Marie R Griffin, Allen S Craig, Cynthia G Whitney, Elizabeth Zell, Catherine A Lexau, Ann R Thomas, Lee H Harrison, Arthur L Reingold, James L Hadler, Monica M Farley, Bridget J Anderson, William Schaffner
Affiliations
- PMID: 16609088
- DOI: 10.1001/jama.295.14.1668
Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine
Katherine A Poehling et al. JAMA. 2006.
Abstract
Context: Streptococcus pneumoniae is a serious infection in young infants. A heptavalent pneumococcal conjugate vaccine (PCV7) was licensed in 2000 and recommended for all children aged 2 to 23 months.
Objective: To determine the rates of invasive pneumococcal disease (IPD) in young infants before and after PCV7 was incorporated into the childhood immunization schedule in June 2000.
Design, setting, and participants: A prospective, population-based study of infants aged 0 to 90 days who resided in areas in 8 US states with active laboratory surveillance for invasive S pneumoniae infections from July 1, 1997, to June 30, 2004.
Main outcome measures: Rates of laboratory-confirmed IPD before (July 1, 1997-June 30, 2000) and after (July 1, 2001-June 30, 2004) PCV7 introduction, excluding a transition year (July 1, 2000-June 30, 2001).
Results: There were 146 cases of IPD, 89 before and 57 after PCV7 introduction. Isolated bacteremia occurred in 94 cases (64%), pneumonia in 27 (18%), meningitis in 22 (15%), and septic arthritis and/or osteomyelitis in 3 (2%). Mean rates of IPD for infants aged 0 to 90 days decreased 40% from 11.8 (95% confidence interval [CI], 9.6-14.5) to 7.2 (95% CI, 5.6-9.4; P = .004) per 100 000 live births following PCV7 introduction. Among black infants, mean rates of IPD decreased significantly from 17.1 (95% CI, 11.9-24.6) to 5.3 (95% CI, 2.8-10.1; P = .001) per 100,000 live births, with a nonsignificant decrease from 9.6 (95% CI, 7.3-12.7) to 6.8 (95% CI, 4.9-9.4) per 100,000 live births for white infants. Rates of PCV7-serotype isolates decreased significantly from 7.3 (95% CI, 5.3-10.1) to 2.4 (95% CI, 1.6-3.8; P<.001) per 100,000 live births, while rates of non-PCV7 serotypes remained stable (P = .55).
Conclusions: Since PCV7 introduction, rates of IPD in young infants have decreased significantly, providing evidence that vaccinating children aged 2 to 23 months has led to changes in pneumococcal carriage in infants too young to receive PCV7. With a significant decrease in rates of IPD among black infants, the previous racial difference has been eliminated.
Similar articles
- Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007.
Hsu KK, Shea KM, Stevenson AE, Pelton SI; Massachusetts Department of Public Health. Hsu KK, et al. Pediatr Infect Dis J. 2010 Apr;29(4):289-93. doi: 10.1097/INF.0b013e3181c15471. Pediatr Infect Dis J. 2010. PMID: 19935447 - Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and wales.
Ladhani SN, Andrews NJ, Waight P, Borrow R, Slack MP, Miller E. Ladhani SN, et al. Clin Infect Dis. 2013 Mar;56(5):633-40. doi: 10.1093/cid/cis934. Epub 2012 Nov 21. Clin Infect Dis. 2013. PMID: 23175560 - Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL. Lacapa R, et al. Clin Infect Dis. 2008 Aug 15;47(4):476-84. doi: 10.1086/590001. Clin Infect Dis. 2008. PMID: 18627249 - [Heptavalent-pneumococcal conjugate vaccine (Prevenar). Differences in effectiveness between populations].
Guevara M, Barricarte A, Pérez B, Arriazu M, García Cenoz M, Castilla J. Guevara M, et al. An Sist Sanit Navar. 2008 May-Aug;31(2):171-92. doi: 10.4321/s1137-66272008000300007. An Sist Sanit Navar. 2008. PMID: 18953365 Review. Spanish.
Cited by
- Synthesis of Streptococcus pneumoniae serotype 9V oligosaccharide antigens.
Parameswarappa SG, Pereira CL, Seeberger PH. Parameswarappa SG, et al. Beilstein J Org Chem. 2020 Jul 15;16:1693-1699. doi: 10.3762/bjoc.16.140. eCollection 2020. Beilstein J Org Chem. 2020. PMID: 32733612 Free PMC article. - On-demand biomanufacturing of protective conjugate vaccines.
Stark JC, Jaroentomeechai T, Moeller TD, Hershewe JM, Warfel KF, Moricz BS, Martini AM, Dubner RS, Hsu KJ, Stevenson TC, Jones BD, DeLisa MP, Jewett MC. Stark JC, et al. Sci Adv. 2021 Feb 3;7(6):eabe9444. doi: 10.1126/sciadv.abe9444. Print 2021 Feb. Sci Adv. 2021. PMID: 33536221 Free PMC article. - Presentation and management of pediatric orbital cellulitis.
Fanella S, Singer A, Embree J. Fanella S, et al. Can J Infect Dis Med Microbiol. 2011 Fall;22(3):97-100. doi: 10.1155/2011/626809. Can J Infect Dis Med Microbiol. 2011. PMID: 22942886 Free PMC article. - Potential impact of accelerating the primary dose of pneumococcal conjugate vaccine in infants.
Stancil JM, Peters TR, Givner LB, Poehling KA. Stancil JM, et al. Arch Pediatr Adolesc Med. 2009 May;163(5):422-5. doi: 10.1001/archpediatrics.2009.39. Arch Pediatr Adolesc Med. 2009. PMID: 19414687 Free PMC article. - Performance of clinical decision aids (CDA) for the care of young febrile infants: a multicentre prospective cohort study conducted in the UK and Ireland.
Umana E, Mills C, Norman-Bruce H, Mitchell H, McFetridge L, Lynn F, McKeeman G, Foster S, Barrett MJ, Roland D, Lyttle MD, Watson C, Waterfield T; Paediatric Emergency Research in the UK and Ireland (PERUKI). Umana E, et al. EClinicalMedicine. 2024 Nov 27;78:102961. doi: 10.1016/j.eclinm.2024.102961. eCollection 2024 Dec. EClinicalMedicine. 2024. PMID: 39677360 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical